With the revival of research interest into psychedelic medicine, neuroscience is experiencing the same revolution oncology once did by discovering new types of medicine a few decades ago. That’s what Osmind CoFounder and CEO Lucia Huang said in an interview with Microdose Content Editor and host of the PsyFi podcast, Gaurav Dubey. In a fascinating exploration of the next generation of digital therapeutics in mental health and psychedelic medicine, Gaurav and Lucia dive deep into Osmind and how it’s poised to disrupt mental healthcare as we currently know it.
Read: How Is Technology Changing the Psychedelic Medicine Landscape?
What is Osmind?
Lucia describes Osmind as software that provides therapists and clinicians with the tools they need to better care for patients that are seeking out psychedelic medicine. They aim to supplement and bolster the patient-doctor relationship by making the overall healing and treatment process more seamless with Osmind.
Lucia also mentioned how patients will get a mobile app that allows them to journal and reflect on their psychedelic experiences, provide feedback about outcomes to their healthcare providers, and facilitate administrative things, like getting insurance reimbursement for their therapies. Considering how frustrating handling things like insurance claims can be today, it’s relieving to know people like Lucia are working to make this process far simpler for the patient when it comes to the future of psychedelic medicine and therapy. In addition to helping the patient, the nature of data aggregation of electronic health records provided by Osmind stands to benefit big pharma in big ways.
Osmind’s Electronic Health Records Software Will Help Big Pharma & Biotech in Big Ways
One major feature of Osmind is that their electronic health records software helps practices aggregate information on how the therapies are working for different patients and be able to do things like help biotech companies better design a clinical trial, better subtype patient populations to predict the best response of a drug candidate so it has the best chance of getting to market. Considering the lion’s share (over 70%) of capital in this space right now is in drug development plays, any tools that can help companies narrow down the best, most promising drug candidates are sure to be incredibly useful today.
Taking an Evidence-Based, Data-Driven Approach to Digital Infrastructure & Therapeutics
With the massive amount of data available to practitioners, from patient histories and genetic testing to biometric data gathered from patients before, during, and after the psychedelic experience, sophisticated digital infrastructure is crucial for successfully implementing psychedelic therapy into mainstream society and modern medicine. Designed specifically for treatment-resistant mental health practices, Osmind aims to fill this growing need for advanced digital architecture to support psychedelic-assisted treatment.
Lucia insightfully mentioned how providers will need time and experience to ultimately establish what treatments work best for which types of people. She mentions in her PsyFi episode with Gaurav, that “with today’s advancements, we’re able to take a more data-driven, evidence-based approach to mental healthcare”. What’s even more exciting about Osmind is that the data they’re collecting goes beyond just improving the patient-doctor relationship, but will also ultimately help reduce stigma and shifting global drug policies. It’s certainly refreshing to hear such ambitious goals from the passionate Lucia and it’s certainly what this space needs right now.
Looking Ahead for Osmind & CoFounder and CEO, Lucia Huang
When asked what she was most excited about in the modern psychedelic renaissance, Lucia answered: “the fact that psychedelic medicine is promising treatments that are more curative in nature.” Indeed, the powerful MAPS Phase 3 MDMA trials demonstrate exactly that—psychedelic medicine works and can be curative for treatment-resistant conditions like PTSD. With psychedelic medicine on its way here, the need for advanced digital architecture to support this paradigm shift in mental healthcare is rapidly increasing. It will be exciting to watch the team at Osmind rise up to meet this need and provide robust digital therapeutics to support this burgeoning field of healthcare.
With the revival of research interest into psychedelic medicine, neuroscience is experiencing the same revolution oncology once did by discovering new types of medicine a few decades ago. That’s what Osmind CoFounder and CEO Lucia Huang said in an interview with Microdose Content Editor and host of the PsyFi podcast, Gaurav Dubey. In a fascinating exploration of the next generation of digital therapeutics in mental health and psychedelic medicine, Gaurav and Lucia dive deep into Osmind and how it’s poised to disrupt mental healthcare as we currently know it.
Read: How Is Technology Changing the Psychedelic Medicine Landscape?
What is Osmind?
Lucia describes Osmind as software that provides therapists and clinicians with the tools they need to better care for patients that are seeking out psychedelic medicine. They aim to supplement and bolster the patient-doctor relationship by making the overall healing and treatment process more seamless with Osmind.
Lucia also mentioned how patients will get a mobile app that allows them to journal and reflect on their psychedelic experiences, provide feedback about outcomes to their healthcare providers, and facilitate administrative things, like getting insurance reimbursement for their therapies. Considering how frustrating handling things like insurance claims can be today, it’s relieving to know people like Lucia are working to make this process far simpler for the patient when it comes to the future of psychedelic medicine and therapy. In addition to helping the patient, the nature of data aggregation of electronic health records provided by Osmind stands to benefit big pharma in big ways.
Osmind’s Electronic Health Records Software Will Help Big Pharma & Biotech in Big Ways
One major feature of Osmind is that their electronic health records software helps practices aggregate information on how the therapies are working for different patients and be able to do things like help biotech companies better design a clinical trial, better subtype patient populations to predict the best response of a drug candidate so it has the best chance of getting to market. Considering the lion’s share (over 70%) of capital in this space right now is in drug development plays, any tools that can help companies narrow down the best, most promising drug candidates are sure to be incredibly useful today.
Taking an Evidence-Based, Data-Driven Approach to Digital Infrastructure & Therapeutics
With the massive amount of data available to practitioners, from patient histories and genetic testing to biometric data gathered from patients before, during, and after the psychedelic experience, sophisticated digital infrastructure is crucial for successfully implementing psychedelic therapy into mainstream society and modern medicine. Designed specifically for treatment-resistant mental health practices, Osmind aims to fill this growing need for advanced digital architecture to support psychedelic-assisted treatment.
Lucia insightfully mentioned how providers will need time and experience to ultimately establish what treatments work best for which types of people. She mentions in her PsyFi episode with Gaurav, that “with today’s advancements, we’re able to take a more data-driven, evidence-based approach to mental healthcare”. What’s even more exciting about Osmind is that the data they’re collecting goes beyond just improving the patient-doctor relationship, but will also ultimately help reduce stigma and shifting global drug policies. It’s certainly refreshing to hear such ambitious goals from the passionate Lucia and it’s certainly what this space needs right now.
Looking Ahead for Osmind & CoFounder and CEO, Lucia Huang
When asked what she was most excited about in the modern psychedelic renaissance, Lucia answered: “the fact that psychedelic medicine is promising treatments that are more curative in nature.” Indeed, the powerful MAPS Phase 3 MDMA trials demonstrate exactly that—psychedelic medicine works and can be curative for treatment-resistant conditions like PTSD. With psychedelic medicine on its way here, the need for advanced digital architecture to support this paradigm shift in mental healthcare is rapidly increasing. It will be exciting to watch the team at Osmind rise up to meet this need and provide robust digital therapeutics to support this burgeoning field of healthcare.